GLP‑1 Pipeline Expansion

Despite the headwinds, Novo maintains growth in its GLP‑1 pipeline. Early‑stage candidates include CagriSema for type‑2 diabetes and Senagametide (formerly amycretin). The company also advanced an oral GLP‑1RA pill, expected to enter the market in the second half of 2025, with the pill version of Wegovy projected to drive significant weight‑loss (16.6 % average) and cardiovascular benefits.